09.07.2021 • NewsNouryonNobian

Nouryon Completes Spin-out of Nobian

Nouryon, the former specialty chemical business of AkzoNobel, has completed the spin-out of its base chemicals business, Nobian. The latter company will be held separately by Nouryon’s private equity owners, the Carlyle Group and GIC.

As part of the spin-out transaction, Nouryon repaid € 1.5 billion of its debt with the proceeds of a completed external financing by Nobian. To help ensure a seamless transformation, Nouryon will continue to provide transitional support services to Nobian across multiple functional areas.

Nouryon, focused globally, specializes in sustainable solutions for manufacturing everyday products in areas such as personal care, cleaning goods, paints & coatings, agriculture and food, along with pharmaceuticals and building products. The company with about 7,900 employees  in more than 80 countries had sales revenues of €3.7 billion in 2020.

Nobian, with a more European focus, produces base chemicals for industries ranging from construction and cleaning to pharmaceuticals and water treatment. The company employs about 1,600 people and posted revenues of €1 billion in 2020.

Charlie Shaver, chairman and CEO of Nouryon and chairman of Nobian, said the split will allow Nouryon to benefit from an “increasingly specialized and leading portfolio in Performance Formulations and Technology Solutions, driven by resilient and growing end-markets.”

Author: Dede Williams, Freelance Journalist

 

Nouryon, AkzoNobel’s former specialty chemical business, has completed the...
Nouryon, AkzoNobel’s former specialty chemical business, has completed the spin-out of its base chemicals business, Nobian. The latter will be held separately by Nouryon’s equity owners, the Carlyle Group and GIC. As part of the spin-out, Nouryon repaid € 1.5 billion of its debt. (c) Nouryon

Company

Logo:

Nouryon

Christian Neefestraat 2
1077 WW Amsterdam
Netherlands

Company contact







Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.